Table 3.
Univariate and multivariate analysis of predictors of hormonal therapy adherence among women diagnosed with breast cancer and treated with adjuvant hormonal therapy, MHS, 2000–2007
| Univariate |
Multivariate |
|||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Age | ||||||
| ≤45.00 years | 1.00 | 1.00 | ||||
| 45.01–55 years | 1.89 | 1.55–2.30 | 0.000 | 1.71 | 1.38–2.13 | 0.000 |
| 55.01–65 years | 3.03 | 2.44–3.75 | 0.000 | 2.41 | 1.87–3.10 | 0.000 |
| 65.01–75 years | 3.24 | 2.55–4.10 | 0.000 | 2.49 | 1.84–3.37 | 0.000 |
| 75.01–85 years | 2.29 | 1.72–3.05 | 0.000 | 2.14 | 1.46–3.14 | 0.000 |
| 85.01+ years | 1.16 | 0.65–2.08 | 0.610 | 1.27 | 0.65–2.50 | 0.481 |
| SES | ||||||
| Lowest quartile | 1.00 | 1.00 | ||||
| Second quartile | 0.95 | 0.78–1.16 | 0.643 | 0.99 | 0.81–1.22 | 0.956 |
| Third quartile | 1.03 | 0.85–1.24 | 0.787 | 1.14 | 0.92–1.41 | 0.226 |
| Highest quartile | 1.07 | 0.87–1.31 | 0.546 | 1.23 | 0.96–1.56 | 0.097 |
| Birth country | ||||||
| Israel | 1.00 | 1.00 | ||||
| Europe | 1.26 | 1.09–1.46 | 0.002 | 1.01 | 0.84–1.20 | 0.929 |
| Asia/Africa | 1.36 | 1.04–1.78 | 0.026 | 0.99 | 0.74–1.33 | 0.955 |
| Other/unknown | 1.50 | 1.04–2.15 | 0.030 | 1.22 | 0.82–1.82 | 0.326 |
| District | ||||||
| Central | 1.00 | 1.00 | ||||
| Southern | 1.17 | 0.92–1.50 | 0.208 | 1.25 | 0.95–1.66 | 0.114 |
| Northern | 0.96 | 0.77–1.19 | 0.700 | 0.97 | 0.76–1.24 | 0.817 |
| Sharon | 1.08 | 0.88–1.34 | 0.455 | 1.10 | 0.88–1.38 | 0.398 |
| Jerusalem area | 1.06 | 0.86–1.31 | 0.567 | 1.10 | 0.87–1.39 | 0.410 |
| Other | 0.60 | 0.43–0.84 | 0.003 | − | ||
| BMI | ||||||
| Underweight | 0.54 | 0.43–0.67 | 0.000 | 0.48 | 0.36–0.63 | 0.000 |
| Normal | 1.00 | 1.00 | ||||
| Overweight | 1.23 | 1.03–1.47 | 0.020 | 1.08 | 0.89–1.32 | 0.414 |
| Obese | 1.27 | 1.06–1.53 | 0.011 | 1.00 | 0.81–1.24 | 0.982 |
| Smoking history | ||||||
| Current | 0.63 | 0.49–0.80 | 0.000 | 0.70 | 0.53–0.91 | 0.009 |
| Past | 1.02 | 0.65–1.61 | 0.932 | 0.90 | 0.55–1.47 | 0.681 |
| Never | 1.00 | 1.00 | ||||
| Other/unknown | 0.49 | 0.37–0.65 | 0.000 | 0.58 | 0.40–0.82 | 0.002 |
| Initial treatment | ||||||
| Tamoxifen | 1.00 | 1.00 | ||||
| AI | 1.44 | 1.04–1.99 | 0.026 | 1.26 | 0.88–1.81 | 0.210 |
| Year of initial treatment | ||||||
| 2000 | 1.00 | 1.00 | ||||
| 2001 | 1.01 | 0.71–1.42 | 0.970 | 0.99 | 0.68–1.46 | 0.979 |
| 2002 | 1.11 | 0.78–1.57 | 0.568 | 1.02 | 0.69–1.50 | 0.929 |
| 2003 | 1.30 | 0.92–1.85 | 0.140 | 1.19 | 0.80–1.77 | 0.379 |
| 2004 | 1.12 | 0.79–1.58 | 0.532 | 1.04 | 0.70–1.54 | 0.838 |
| 2005 | 1.20 | 0.86–1.67 | 0.295 | 1.05 | 0.72–1.53 | 0.808 |
| 2006 | 1.25 | 0.89–1.75 | 0.196 | 1.01 | 0.70–1.48 | 0.943 |
| 2007 | 1.25 | 0.89–1.74 | 0.193 | 1.09 | 0.75–1.60 | 0.647 |
| 2008 | 1.11 | 0.76–1.63 | 0.590 | 1.04 | 0.67–1.59 | 0.871 |
| Hypertension | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.78 | 1.53–2.08 | 0.000 | 1.46 | 1.19–1.79 | 0.000 |
| Osteoporosis | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.41 | 1.14–1.74 | 0.001 | 1.07 | 0.84–1.36 | 0.590 |
| Chronic kidney disease | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.20 | 0.92–1.56 | 0.184 | 0.91 | 0.67–1.24 | 0.547 |
| Cardiovascular disease | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.16 | 0.92–1.45 | 0.208 | 0.89 | 0.68–1.17 | 0.419 |
| Diabetes mellitus | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.38 | 1.10–1.73 | 0.005 | 0.92 | 0.71–1.19 | 0.520 |